The Swiss life-sciences company said it expected accelerated sales growth in the fourth quarter on the back of the timing of ...

Sunir Garg, MD, shares insights on new data on aflibercept 8 mg, faricimab, and the impact of social determinants of health, ...

Be Biopharma has raised $82m in financing to advance a gene therapy targeting hemophilia B to a Phase I/II trial, whilst also ...

Sandoz, Eli Lilly, Bayer, and Genentech executives tell what strikes them about the 2024 presidential race — and how the ...

Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination ...

The allergy treatment market is set to experience robust growth, with an estimated valuation of US$ 20.20 billion in 2022 and ...

Regulators are supposed to abide by society's “bargain” with them: Civil servants are granted lifetime tenure and protected ...

Lonza Group AG / Key word (s): Quarter Results Q3 2024 Qualitative Update: Lonza Confirms Full-Year Outlook 2024 24-Oct-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR ...

The global cryoglobulinemia treatment market is poised for significant growth, with an expected market value of US$ 496 ...

Studies have called into question whether patients with HER2-low breast cancer are being identified and classified accurately.

PARIS--Evexta Bio SA, a clinical-stage biotechnology company focused on developing first-in-class therapies in oncology, announces the appointment of Edith A. Perez as Scientific Advisor.